We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Leap Therapeutics Inc (LPTX) USD0.001

Sell:$2.29 Buy:$2.31 Change: $0.14 (6.48%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.14 (6.48%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.14 (6.48%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing targeted and immuno-oncology therapeutics. Its advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-related protein 1 (DKK1) protein. DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. Its second clinical-stage program is FL-301, a humanized monoclonal antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer. It also has two preclinical antibody programs, FL-302 and FL-501. FL-302 is a Claudin18.2/CD137 (also known as 4-1BB) bispecific antibody that is in preclinical development. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.

Contact details

47 Thorndike St Ste B1-1
United States
+1 (617) 2524343

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$87.24 million
Shares in issue:
38.26 million
United States
US dollar

Key personnel

  • Christopher Mirabelli
    Chairman of the Board
  • Douglas Onsi
    President, Chief Executive Officer, Director
  • Augustine Lawlor
    Chief Operating Officer
  • Jason Baum
    Chief Scientific Officer
  • Christine Granfield
    Vice President, Head - Regulatory Affairs and Quality
  • Mark O'Mahony
    Chief Manufacturing Officer
  • Cynthia Sirard
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.